 The purpose of this study in patients with chronic stable coronary artery disease treatable by percutaneous coronary intervention PCI is to evaluate the long-term efficacy and safety of the orally taken selective If-inhibitor Ivabradine Procoralan, Servier Switzerland with regard to the promotion of collateral growth. 